Showing 20 of 83 recruiting trials for “t-cell-large-granular-lymphocyte-leukemia”
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
👨⚕️ John C Reneau, MD, PhD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started May 2022View details ↗
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
👨⚕️ Barbara Eichhorst, MD, Prof., Department I of Internal Medicine, University Hospital Cologne📍 30 sites📅 Started Apr 2022View details ↗
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial
👨⚕️ Daniel Ermann, MD, Huntsman Cancer Institute/ University of Utah📍 1 site📅 Started Jan 2022View details ↗
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
👨⚕️ Natalie Grover, MD, UNC Lineberger Comprehensive Cancer Center📍 1 site📅 Started Nov 2020View details ↗
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
👨⚕️ Christine E Gruessner, M.D., National Heart, Lung, and Blood Institute (NHLBI)📍 1 site📅 Started Jun 2019View details ↗
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingNCT03501576 ↗
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
RecruitingNCT03342144 ↗
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
RecruitingNCT03375619 ↗
Long-term Follow-up Study of Patients Receiving CAR-T Cells
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →